Cargando…
Penalized Model‐Based Unsupervised Phenomapping Unravels Distinctive HFrEF Phenotypes With Improved Outcomes Discrimination From Sacubitril/Valsartan Treatment Independent of MAGGIC Score
BACKGROUND: The angiotensin receptor–neprilysin inhibitor (LCZ696) has emerged as a promising pharmacological intervention against renin–angiotensin system inhibitor in reduced ejection fraction heart failure (HFrEF). Whether the therapeutic benefits may vary among heterogeneous HFrEF subgroups rema...
Autores principales: | Sung, Kuo‐Tzu, Chang, Hung‐Yu, Hsu, Nai‐Wei, Huang, Wen‐Hung, Lin, Yueh‐Hung, Yun, Chun‐Ho, Hsiao, Chih‐Chung, Hsu, Chien‐Yi, Tsai, Shin‐Yi, Chen, Ying‐Ju, Tsai, Cheng‐Ting, Su, Cheng‐Huang, Hung, Ta‐Chuan, Hou, Charles Jia‐Yin, Yeh, Hung‐I, Hung, Chung‐Lieh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547272/ https://www.ncbi.nlm.nih.gov/pubmed/37681571 http://dx.doi.org/10.1161/JAHA.122.028860 |
Ejemplares similares
-
Sacubitril/valsartan in HFrEF – Should the aces up our sleeves be played earlier?
por: Boehmer, Andreas A., et al.
Publicado: (2019) -
Sacubitril/Valsartan vs. Standard Medical Therapy on Exercise Capacity in HFrEF Patients
por: Campanile, Alfonso, et al.
Publicado: (2023) -
Our Experience With Sacubitril/Valsartan in Chronic Heart Failure Management - HFrEF in the Ambulatory Setting
por: Naser, Nabil, et al.
Publicado: (2022) -
Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF
por: Visco, Valeria, et al.
Publicado: (2022) -
Qili Qiangxin Capsule Combined With Sacubitril/Valsartan for HFrEF: A Systematic Review and Meta-Analysis
por: Xiang, Qian, et al.
Publicado: (2022)